⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NRSN News
NeuroSense Therapeutics Ltd. Ordinary Shares
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
prnewswire.com
NRSN
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
prnewswire.com
NRSN
NeuroSense to Host Investor Webinar on December 8, 2025
prnewswire.com
NRSN
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
prnewswire.com
NRSN
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
prnewswire.com
NRSN
NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026
prnewswire.com
NRSN